Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nintedanib skin disease compositions and methods for treating neovascularization

A technology for skin diseases and new blood vessels, applied in the field of medicine, can solve skin diseases without nintedanib, can not solve the problem of new blood vessels, skin abnormalities and other problems

Inactive Publication Date: 2022-04-26
张国华
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Many existing skin diseases are related to the proliferation of new blood vessels, leading to local abnormalities in the skin. However, the existing products cannot solve the problems caused by new blood vessels during the treatment process. Currently, nintedanib has not been used to treat skin diseases with new blood vessels. Methods

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Embodiment 1: The purpose of the present invention is to provide a new application of nintedanib, and further tests will be carried out on the treatment of animal experimental models.

[0018] Test materials: 100 SD rats with skin disease of neovascularization;

[0019] Reagent: nintedanib purity 99.97%);

[0020] Nintedanib is added with auxiliary materials to make ointment for external use, such as 1 part of Nintedanib, 10 parts of white petrolatum, and 10 parts of propylene glycol. After mixing, Nintedanib cream for external use is obtained. There is no obvious acute toxic reaction, no irritation, and no local and systemic allergic reactions when applied to the skin of rats.

Embodiment 2

[0021] Embodiment 2: Test material: 100 SD rats with skin disease of neovascularization;

[0022] Reagent: nintedanib purity 99.97%);

[0023] Nintedanib is added with auxiliary materials to make ointment for external use, such as 10 parts of Nintedanib, 10 parts of white petrolatum, and 10 parts of propylene glycol. After mixing, Nintedanib cream for external use is obtained. There is no obvious acute toxic reaction, no irritation, and no local and systemic allergic reactions when applied to the skin of rats.

Embodiment 3

[0024] Embodiment 3: Test material: 100 SD rats with skin disease of neovascularization;

[0025] Reagent: nintedanib purity 99.97%);

[0026] Nintedanib is made into external ointment by adding auxiliary materials, such as 30 parts of Nintedanib, 10 parts of white petrolatum, and 10 parts of propylene glycol, and after mixing, Nintedanib cream for external use is obtained. There is no obvious acute toxic reaction, no irritation, and no local and systemic allergic reactions when applied to the skin of rats.

[0027] Treatment days Embodiment 1 (therapeutic rate %) Embodiment 2 (therapeutic rate %) Embodiment 2 (therapeutic rate %) 10 days 10 20 30 20 days 20 40 70 30 days 40 60 90

[0028] According to the above results, it is shown that nintedanib has a good therapeutic effect on the treatment of skin diseases caused by neovascularization.

[0029] Therefore, the nintedanib method for treating skin diseases caused by neovasculariza...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a nintedanib composition and method for treating skin diseases formed by neovascularization. The nintedanib composition is prepared into a medicament by adding auxiliary materials, and local administration can accelerate skin disease healing and restore to normal. The nintedanib is used for clinically treating the skin diseases caused by neovascularization, patients can be helped to recover as soon as possible, the skin can be kept in the original shape as far as possible, new medical application of the nintedanib is explored, a new application field is developed, and the nintedanib has great significance in treatment of the skin diseases caused by neovascularization.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a nintedanib composition and method for treating skin diseases of neovascularization. Background technique [0002] Nintedanib is a novel angiogenesis inhibitor that can simultaneously act on three key receptor families involved in angiogenesis: vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) ) and fibroblast growth factor receptor (FGFR). Nintedanib has been approved by the FDA and EMA for the treatment of idiopathic pulmonary fibrosis (IPF), and has also been approved by the EMA for use in combination with docetaxel after first-line chemotherapy for locally advanced adenocarcinoma diagnosed by histology or adult patients with metastatic or locally recurrent non-small cell lung cancer (NSCLC). Many existing skin diseases are related to the proliferation of new blood vessels, leading to local abnormalities in the skin. Howev...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/496A61P17/00A61P9/14A61P29/00A61P37/08A61P37/02A61P35/00A61P17/06A61P31/10A61P17/02A61P31/12A61P31/04A61P33/00
CPCA61K31/496A61K9/0019A61K9/0014A61P17/00A61P9/14A61P29/00A61P37/08A61P37/02A61P35/00A61P17/06A61P31/10A61P17/02A61P31/12A61P31/04A61P33/00
Inventor 张国华
Owner 张国华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com